「to」の検索結果
410件：361～365件目を表示
-
compound (development code: SJP-0132) discovered by Mochida Pharmaceutical Co., Ltd. (Head office: Tokyo, Japan; President: Mr. Naoyuki Mochida; hereinafter: Mochida) as an eye drop treatment for Dry...
https://www.senju.co.jp/system/files/content_news/2024-07/ENG_20240716_0.pdf -
esident: Mr. Shuhei Yoshida; hereinafter “Senju”) hereby announces that the orphan drug designation to the in-house developed compound having the development code SJP-0008 was granted by the Ministry ...
https://www.senju.co.jp/system/files/content_news/2024-07/ENG_20240708_0.pdf -
Milestones in Our History | About Senju | SENJU Pharmaceutical
unched 1949 February Reishin Tanimura became the President. September Company head office relocated to Higashi-ku, Osaka. Manufacturing plant relocated to Ashiya-shi, Hyogo. 1951 June Agreement for th...
https://www.senju.co.jp/english/about/history.html -
esident: Mr. Shuhei Yoshida; hereinafter “Senju”) hereby announces that the orphan drug designation to the in-house developed compound having the development code SJP-0008 was granted by the Ministry ...
https://www.senju.co.jp/system/files/content_news/2024-07/ENG_20240708.pdf -
ntagonist (development code: SJP-0132) discovered by Mochida Pharmaceutical Co., Ltd. (Head office: Tokyo, Japan; President: Mr. Naoyuki Mochida; hereinafter: Mochida) and licensed to Senju as an eye ...
https://www.senju.co.jp/system/files/content_news/2025-01/ENG_20250117_0.pdf